Abstracts tagged "Polymyalgia Rheumatica (PMR)"

Abstract Number: 0768 • ACR Convergence 2024
Addressing Gaps in Polymyalgia Rheumatica: A Systematic Literature Review
Shelley Fritz¹, Angela Degrassi², Kelly Gavigan², Ruohan Hong³, Santiago Munoz Perez², Esteban Rivera⁴, Erik Stone⁵, Laura Stradford⁶, Ambika Vartak², Anne Sydor² and Shilpa Venkatachalam³, ¹Global Healthy Living Foundation, Kalaheo, HI, ²Global Healthy Living Foundation, Upper Nyack, NY, ³Global Healthy Living Foundation, New York, NY, ⁴Global Healthy Living Foundation, Long Island City, NY, ⁵Global Healthy Living Foundation, Upper Nyack, ⁶Global Healthy Living Foundation, Nyack, NY
Background/Purpose: This systematic literature review on polymyalgia rheumatica (PMR) and PMR with giant cell arteritis (GCA) evaluates existing literature on disease burden, management, and treatment…
Abstract Number: 1704 • ACR Convergence 2024
Cluster Analysis of Peripheral Blood Mononuclear Cell Subpopulations Using Deep Immunophenotyping, Multiplex Serum Cytokines and Small Lipid Mediators at the Very Early Stages of Steroid Treatment in Polymyalgia Rheumatica and Giant Cell Arteritis
Dimitrios Anastasios Palamidas¹, Maria Papadaki², Nikolaos Paschalidis³, Eleftherios Pavlos⁴, Loukas chatzis¹, Ourania Argyropoulou⁵, Panagiota Palla⁵, Ioanna-Evdokia Galani⁶, Andreas Goules⁷, Evangelos Andreakos⁴ and Athanasios Tzioufas⁸, ¹Pathophysiology Department, Athens School of Medicine, National and Kapodistrian University of Athens, Athens, Greece, Cholargos Athens, Greece, ²Laboratory of Immunobiology, Center for Clinical, Experimental Surgery and Translational Research, Biomedical Research Foundation of the Academy of Athens, Athens, 115 27, Greece., Cholargos Athens, Attiki, Greece, ³Mass Cytometry-CyTOF Laboratory, Center for Clinical Research, Experimental Surgery and Translational Research, Biomedical Research Foundation of the Academy of Athens, Athens, Greece, Cholargos Athens, Greece, ⁴Laboratory of Immunobiology, Center for Clinical, Experimental Surgery and Translational Research, Biomedical Research Foundation of the Academy of Athens, Athens, 115 27, Greece., Athens, Greece, ⁵Department of Pathophysiology, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece., Athens, Greece, ⁶Laboratory of Immunobiology, Center for Clinical, Experimental Surgery and Translational Research, Biomedical Research Foundation of the Academy of Athens, Athens, 115 27, Greece., Cholargos Athens, Greece, ⁷GENERAL HOSPITAL LAIKO ATHENS, Athens, Greece, ⁸LAIKO HOSPITAL, Athens, Greece
Background/Purpose: Polymyalgia Rheumatica (PMR) and Giant Cell Arteritis (GCA) are autoimmune/autoinflammatory disorders affecting patients over 50 years and are characterized by an acute inflammatory response.…
Abstract Number: 0769 • ACR Convergence 2024
Baseline Evaluation of Diagnoses and Prescribing Patterns in Polymyalgia Rheumatica
Laura Stradford¹, Shilpa Venkatachalam², Kelly Gavigan³, Angela Degrassi³, Emily Holladay⁴, Fenglong xie⁵, Yujie Su⁶, Shanette Daigle⁷ and Jeffrey Curtis⁸, ¹Global Healthy Living Foundation, Nyack, NY, ²Global Healthy Living Foundation, New York, NY, ³Global Healthy Living Foundation, Upper Nyack, NY, ⁴University of Alabama at Birmingham, Birmingham, AL, ⁵University of Alabama at Birmingham; Illumination Health, Birmingham, AL, ⁶Illumination Health, Hoover, AL, ⁷FASTER, Birmingham, AL, ⁸University of Alabama at Birmingham, Hoover, AL
Background/Purpose: Polymyalgia rheumatica (PMR) is a chronic inflammatory rheumatic condition that affects approximately 800,000 people in the U.S., occurring almost exclusively after age 50. Moreover,…
Abstract Number: 1725 • ACR Convergence 2024
Exploring Risks of Polymyalgia Rheumatica (PMR), Giant Cell Arteritis (GCA) and Complications While Receiving Immune Checkpoint Inhibitors: Comparative Analysis
Irakli Tskhakaia and Arthur Lau, Jefferson Einstein Hospital, Philadelphia, PA
Background/Purpose: Immune checkpoint inhibitors (ICIs) have transformed cancer treatment, offering significant benefits in various malignancies. However, these therapies can induce immune-related adverse events (irAEs), including…
Abstract Number: 0720 • ACR Convergence 2023
Cognitive Function and Its Associated Factors in Polymyalgia Rheumatica
Patricia Harkins¹, Sharon Cowley², David Kane³ and Richard Conway⁴, ¹St James's Hospital, Dublin, Ireland, ²Tallaght University Hospital, Dublin, Dublin, Ireland, ³Tallaght University Hospital & Trinity College Dublin, Dublin, Ireland, ⁴Trinity College Dublin, Dublin, Ireland
Background/Purpose: Over the past decade our understanding of the prevalence, and indeed impact of cognitive impairment in rheumatic diseases has increased. Intact cognitive function is…
Abstract Number: 2395 • ACR Convergence 2023
Recommendations for Early Referral of Patients with Suspected Polymyalgia Rheumatica: An Initiative from the International Giant Cell Arteritis and Polymyalgia Rheumatica Study Group
Kresten Keller¹, Chetan Mukhtyar², Andreas Wiggers Nielsen³, Andrea Hemmig⁴, Sarah Mackie⁵, Sebastian Sattui⁶, Ellen Margrethe Hauge³, Anisha Dua⁷, Toby Helliwell⁸, Lorna Neil⁹, Daniel Blockmans¹⁰, Valerie Devauchelle¹¹, eric Hayes³, Annett Jansen Venneboer¹², Sara Monti¹³, Cristina Ponte¹⁴, Eugenio De Miguel¹⁵, Mark Matza¹⁶, Kenneth Warrington¹⁷, Kevin Byram¹⁸, Kinanah Yaseen¹⁹, Christine Peoples²⁰, Mike Putman²¹, Lindsay Lally²², Michael Finikiotis²⁰, Simone Appenzeller²³, Ugo Carmori²³, CARLOS ENRIQUE TORO GUTIERREZ²⁴, Elisabeth Backhouse²⁵, Maria Camila Guerrero²⁶, Victor Pimentel-Quiroz²⁷, Helen Keen²⁵, Claire Owen²⁸, Thomas Daikeler²⁹, Annette De Thurah³, Wolfgang Schmidt³⁰, Elisabeth Brouwer¹² and Christian Dejaco³¹, ¹Department of Rheumatology, Aarhus University Hospital; Department of Clinical Medicine, Aarhus University, Aarhus, Denmark, ²Vasculitis service, Rheumatology department, Norfolk and Norwich University Hospital, Norwich, United Kingdom, ³Aarhus University Hospital, Aarhus, Denmark, ⁴University of Basel, Basel, Switzerland, ⁵Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK; Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, ⁶University of Pittsburgh, Pittsburgh, PA, ⁷Northwestern University, Chicago, IL, ⁸Keele University, Keele, United Kingdom, ⁹Polymyalgia Rheumatica and Giant Cell Arteritis Scotland, Perth, United Kingdom, ¹⁰Department of General Internal Medicine, University Hospitals Leuven, Department of Microbiology, Immunology, and Transplantation, KU Leuven, Leuven, Belgium, ¹¹UBO, Brest, France, ¹²University Medical Center Groningen, Groningen, Netherlands, ¹³Division of Rheumatology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy; Department of Internal Medicine and Therapeutics, Università di Pavia, Pavia, Italy, ¹⁴Department of Rheumatology, Centro Hospitalar Universitário Lisboa Norte, Centro Académico de Medicina de Lisboa, Lisbon, Portugal; Rheumatology Research Unit, Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, Centro Académico de Medicina de Lisboa, Lisbon, Portugal, ¹⁵Hospital Universitario La Paz, Madrid, Spain, ¹⁶Massachusetts General Hospital, Newton, MA, ¹⁷Mayo Clinic, Rochester, MN, ¹⁸Vanderbilt University Medical Center, Nashville, TN, ¹⁹Cleveland Clinic, Cleveland, OH, ²⁰University of Pittsburgh Medical Center, Pittsburgh, PA, ²¹Division of Rheumatology, Medical College of Wisconsin, Milwaukee, WI, ²²Hospital for Special Surgery, New York, NY, ²³UNICAMP, Campinas, Brazil, ²⁴Centro de Estudios de Reumatología y Dermatología SAS, Cali, Colombia, ²⁵University of Western Australia, Daglish, Australia, ²⁶General practice, Cali, Colombia, ²⁷Universidad Cientifica del Sur/Hospital Guillermo Almenara Irigoyen, EsSalud, Lima, Peru, ²⁸Austin Health, Malvern East, Australia, ²⁹Clinic for Rheumatology, University Hospital Basel, Basel, Switzerland, ³⁰Rheumatology, Immanuel Krankenhaus Berlin, Medical Centre for Rheumatology Berlin-Buch, Berlin, Germany, ³¹Azienda Sanitaria Alto Adige, Brunico, Italy
Background/Purpose: Existing EULAR/ACR guidelines on polymyalgia rheumatica (PMR) are focused on the management by rheumatologists. However, there is no consensus regarding early referral and evaluation…
Abstract Number: 0721 • ACR Convergence 2023
Characterization of Numeric Rating Scales for Symptom Assessment in Polymyalgia Rheumatica
Tonya K Marmon¹, Jason C Cole², Claire Owen³, Sarah Mackie⁴ and David Katz⁵, ¹Marmon Biostatistics, Seattle, WA, ²P3 Research Consulting, Torrance, CA, ³Austin Health, Malvern East, Australia, ⁴Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK; Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, ⁵Sparrow Pharmaceuticals, Portland, OR
Background/Purpose: Pain, stiffness, and fatigue have been defined as core assessment domains in polymyalgia rheumatica (PMR) by the OMERACT PMR Working Group (PMRWG). Patient partners…
Abstract Number: 2404 • ACR Convergence 2023
Subclinical Giant Cell Arteritis in Polimialgia Rheumatica: A Biomarker of High Relapse Risk
Eugenio De Miguel¹, Rositsa Karalilova², PIERLUIGI MACCHIONI³, Cristina Ponte⁴, Edoardo Conticini⁵, Alessandro Tomelleri⁶, Sara Monti⁷, Irene Monjo¹, Zguro Batalov², Giulia Klinowski⁸, Paolo Falsetti⁹, David Kane¹⁰, Corrado Campochiaro¹¹ and Alojzija Hocevar¹², ¹Hospital Universitario La Paz, Madrid, Spain, ²Medical University of Plovdiv, University Hospital Kaspela, Plovdiv, Bulgaria, ³Azienda USL -IRCCS di Reggio Emilia, Reggio Emilia, Italy, ⁴Department of Rheumatology, Centro Hospitalar Universitário Lisboa Norte, Centro Académico de Medicina de Lisboa, Lisbon, Portugal; Rheumatology Research Unit, Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, Centro Académico de Medicina de Lisboa, Lisbon, Portugal, ⁵Tallaght University Hospital, Dublin, Ireland, ⁶Unit of Immunology, Rheumatology, Allergy and Rare Diseases, San Raffaele Scientific Institute, Milano, Italy, ⁷Division of Rheumatology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy; Department of Internal Medicine and Therapeutics, Università di Pavia, Pavia, Italy, ⁸IRCCS-S.Maria Nuova, Reggio Emilia, Italy, ⁹San Raffaele Scientific Institute, Siena, Italy, ¹⁰Tallaght University Hospital & Trinity College Dublin, Dublin, Ireland, ¹¹IRCCS San Raffaele Hospital, Unit of Immunology, Rheumatology, Allergy and Rare Disease. Vita-Salute San Raffaele University, Milan, Italy, ¹²Department of Rheumatology, Universitiy Medical Centre Ljubljana, Ljubljana, Slovenia
Background/Purpose: Around 20% of polymyalgia rheumatica (PMR) patients without clinical symptoms of giant cell arteritis (GCA) have subclinical GCA by image or byopsy1. However, there…
Abstract Number: 0747 • ACR Convergence 2023
Clinical Phenotype of Patients with Subclinical Giant Cell Arteritis in Polymyalgia Rheumatica
Sharon Cowley¹, Colm Kirby², Patricia Harkins³, Richard Conway⁴ and David Kane⁵, ¹Tallaght University Hospital, Dublin, Dublin, Ireland, ²Tallaght University Hospital, Dublin, Ireland, ³St James's Hospital, Dublin, Ireland, ⁴Trinity College Dublin, Dublin, Ireland, ⁵Tallaght University Hospital & Trinity College Dublin, Dublin, Ireland
Background/Purpose: It has been reported that more than a quarter of patients with polymyalgia rheumatica (PMR) have subclinical giant cell arteritis (GCA). It remains unclear…
Abstract Number: 2516 • ACR Convergence 2023
The Effect of Starting Prednisone Dose on the Treatment of Polymyalgia Rheumatica
Katrina Nguyen¹, Jennifer Du¹, Jiaxiao shi² and Antony Lin¹, ¹Kaiser SCAL, Fontana, CA, ²SCPMG, Pasadena, CA
Background/Purpose: Polymyalgia rheumatica (PMR) is a systemic inflammatory syndrome that is characterized by widespread pain and stiffness around the shoulders, pelvic girdle and neck. PMR…
Abstract Number: 1036 • ACR Convergence 2023
The Prevalence of Shoulder and Hip Joints Ultrasound Findings in Polymyalgia Rheumatica: A Multicenter International Study
Alojzija Hocevar¹, PIERLUIGI MACCHIONI², Irene Monjo³, Rositsa Karalilova⁴, Edoardo Conticini⁵, Alessandro Tomelleri⁶, Cristina Ponte⁷, Sara Monti⁸, Giulia Klinowski⁹, Zguro Batalov⁴, Paolo Falsetti¹⁰, Corrado Campochiaro¹¹ and Eugenio De Miguel³, ¹Department of Rheumatology, Universitiy Medical Centre Ljubljana, Ljubljana, Slovenia, ²Azienda USL -IRCCS di Reggio Emilia, Reggio Emilia, Italy, ³Hospital Universitario La Paz, Madrid, Spain, ⁴Medical University of Plovdiv, University Hospital Kaspela, Plovdiv, Bulgaria, ⁵Tallaght University Hospital, Dublin, Ireland, ⁶Unit of Immunology, Rheumatology, Allergy and Rare Diseases, San Raffaele Scientific Institute, Milano, Italy, ⁷Department of Rheumatology, Centro Hospitalar Universitário Lisboa Norte, Centro Académico de Medicina de Lisboa, Lisbon, Portugal; Rheumatology Research Unit, Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, Centro Académico de Medicina de Lisboa, Lisbon, Portugal, ⁸Division of Rheumatology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy; Department of Internal Medicine and Therapeutics, Università di Pavia, Pavia, Italy, ⁹IRCCS-S.Maria Nuova, Reggio Emilia, Italy, ¹⁰San Raffaele Scientific Institute, Siena, Italy, ¹¹IRCCS San Raffaele Hospital, Unit of Immunology, Rheumatology, Allergy and Rare Disease. Vita-Salute San Raffaele University, Milan, Italy
Background/Purpose: Musculoskeletal ultrasound (US) is a validated method for the objective assessment of the pathological changes occurring in PMR. It assists the diagnosis of the…
Abstract Number: 1054 • ACR Convergence 2023
Immune Checkpoint Inhibitor Induced Polymyalgia Rheumatica Demonstrates a Similar Scintigraphic Appearance to Classical Polymyalgia Rheumatica on 18F-Fluorodeoxyglucose PET/CT
David Liew¹, Aurora Poon¹, Christopher McMaster², Russell Buchanan¹, Victor Yang¹, Andrew Scott¹ and Claire Owen³, ¹Austin Health, Heidelberg, Australia, ²Austin Health, Pascoe Vale South, Australia, ³Austin Health, Malvern East, Australia
Background/Purpose: Of the rheumatic immune-related adverse events that follow immune checkpoint inhibitor (ICI) cancer immunotherapy, de novo PMR-like episodes without inflammatory arthritis (ICI-PMR) appear to…
Abstract Number: 1098 • ACR Convergence 2023
Improving Osteoporosis Screening in Patients with Polymyalgia Rheumatica and Giant Cell Arteritis
Kelly Tran¹, Ellen Ann Sockman¹, Rachel Salyer¹, Megan Young¹, Aisha Abbasi¹ and Devanshu Verma², ¹West Virginia University Hospital, Morgantown, WV, ²West Virginia University, Morgantown, WV
Background/Purpose: Osteoporosis is a medical condition associated with decreased bone mass and bone architecture, which increases incidence of fragility fractures(4). It is associated with 1.5…
Abstract Number: 1133 • ACR Convergence 2023
Exploring the Clinical Characteristics and Correlation with Corticosteroid Dependence in Polymyalgia Rheumatica (PMR) Patients: Insights from an Academic Center
William Rigby¹, Todd Mackenzie², Emily Campbell¹, Joshua Skydel³, Bryan Savage¹, Monica Dimambro² and Vivekanand Tiwari¹, ¹Dartmouth Hitchcock Medical Center, Lebanon, NH, ²Dartmouth College, Hanover, NH, ³Dartmouth-Hitchcock Medical Center, Lebanon, NH
Background/Purpose: Polymyalgia rheumatica (PMR) treatment is primarily based on long-term corticosteroids, which results in significant toxicities. Studies1,2 have shown that patients with PMR are exposed…
Abstract Number: 1201 • ACR Convergence 2023
Frailty and Its Impact on Patient Reported Outcomes in Polymyalgia Rheumatica
Patricia Harkins¹, Sharon Cowley², David Kane³ and Richard Conway⁴, ¹St James's Hospital, Dublin, Ireland, ²Tallaght University Hospital, Dublin, Dublin, Ireland, ³Tallaght University Hospital & Trinity College Dublin, Dublin, Ireland, ⁴Trinity College Dublin, Dublin, Ireland
Background/Purpose: Frailty is an increasingly important construct in the field of rheumatology, aiding the identification of individuals with increased vulnerability to accelerated clinical decline and…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].